Outcome of childhood acute lymphoblastic leukemia in Jordan
Background Accurate data about childhood acute lymphoblastic leukemia (ALL) in low‐ and middle‐income countries are lacking. Our study is designed to assess survival of childhood ALL at King Hussein Cancer Center (KHCC) using modified St. Jude Children's Research Hospital protocols. Patients an...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2011-09, Vol.57 (3), p.385-391 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 391 |
|---|---|
| container_issue | 3 |
| container_start_page | 385 |
| container_title | Pediatric blood & cancer |
| container_volume | 57 |
| creator | Halalsheh, Hadeel Abuirmeileh, Najyah Rihani, Rawad Bazzeh, Faiha Zaru, Luna Madanat, Faris |
| description | Background
Accurate data about childhood acute lymphoblastic leukemia (ALL) in low‐ and middle‐income countries are lacking. Our study is designed to assess survival of childhood ALL at King Hussein Cancer Center (KHCC) using modified St. Jude Children's Research Hospital protocols.
Patients and methods
We reviewed the medical records of children 1–18 years of age who were diagnosed with ALL and treated at KHCC from January 2003 through December 2009. Disease characteristics and outcome were analyzed.
Results
Over a 7‐year period, 300 children with ALL were treated. One hundred and seventy‐three (57.7%) were males and 127 (42.3%) were females. The median age at diagnosis was 5 years. One hundred and fifty‐seven (52.3%) children were classified as low‐risk, 118 (39.3%) were standard‐risk and 25 (8.3%) were high‐risk. Two hundred and sixty‐two (88.5%) children had pre‐B cell phenotype and 34 (11.5%) had T‐cell phenotype. Two hundred and seventy‐three (91.3%) children were classified as having CNS I disease, 24 (8%) had CNS II, and 2 (0.67%) had CNS III. Cytogenetic abnormalities included: t(12;21) in 30 (12%) children and t(9;22) in 18 (7.4%). Four (1.3%) children died in induction, 6 (2%) died in first remission and 27 (9%) relapsed. After a median follow‐up of 34.5 months (range 0.32–84.5), the estimated 5‐year event free survival and overall survival were 80% and 89%, respectively.
Conclusion
Treatment protocols developed by major cooperative groups and institutions to treat childhood ALL was successfully adapted and suggest that such an approach may be useful in other low‐ and middle‐income countries. Pediatr Blood Cancer 2011; 57: 385–391. © 2011 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pbc.23065 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_876192432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>876192432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4615-4f205afa077f8d1c683eeb44950dd6595d811de098235ad4c73462077ea1924b3</originalsourceid><addsrcrecordid>eNp90DtPwzAUBWALgSivgT-AsgFDit92xEQrnqooiCIkFsuxHTWQ1CVOBP33GArdYLp3-M4ZDgD7CPYRhPhknps-JpCzNbCFGGUpg0isr36Y9cB2CC-RcsjkJuhhRHjkcgucjrvW-NolvkjMtKzs1HubaNO1LqkW9Xzq80qHtjRJ5bpXV5c6KWfJjW-snu2CjUJXwe393B3weHE-GV6lo_Hl9fBslBrKEUtpgSHThYZCFNIiwyVxLqc0Y9BazjJmJULWwUxiwrSlRhDKcdROowzTnOyAw2XvvPFvnQutqstgXFXpmfNdUFLwL0hwlEf_SgQxlBQLJCI9XlLT-BAaV6h5U9a6WUSkvlZVcVX1vWq0Bz-1XV47u5K_M0ZwsgTvZeUWfzepu8HwtzJdJsrQuo9VQjevigsimHq6vVToQU4m9_fPakA-AdHejhg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020842717</pqid></control><display><type>article</type><title>Outcome of childhood acute lymphoblastic leukemia in Jordan</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Halalsheh, Hadeel ; Abuirmeileh, Najyah ; Rihani, Rawad ; Bazzeh, Faiha ; Zaru, Luna ; Madanat, Faris</creator><creatorcontrib>Halalsheh, Hadeel ; Abuirmeileh, Najyah ; Rihani, Rawad ; Bazzeh, Faiha ; Zaru, Luna ; Madanat, Faris</creatorcontrib><description>Background
Accurate data about childhood acute lymphoblastic leukemia (ALL) in low‐ and middle‐income countries are lacking. Our study is designed to assess survival of childhood ALL at King Hussein Cancer Center (KHCC) using modified St. Jude Children's Research Hospital protocols.
Patients and methods
We reviewed the medical records of children 1–18 years of age who were diagnosed with ALL and treated at KHCC from January 2003 through December 2009. Disease characteristics and outcome were analyzed.
Results
Over a 7‐year period, 300 children with ALL were treated. One hundred and seventy‐three (57.7%) were males and 127 (42.3%) were females. The median age at diagnosis was 5 years. One hundred and fifty‐seven (52.3%) children were classified as low‐risk, 118 (39.3%) were standard‐risk and 25 (8.3%) were high‐risk. Two hundred and sixty‐two (88.5%) children had pre‐B cell phenotype and 34 (11.5%) had T‐cell phenotype. Two hundred and seventy‐three (91.3%) children were classified as having CNS I disease, 24 (8%) had CNS II, and 2 (0.67%) had CNS III. Cytogenetic abnormalities included: t(12;21) in 30 (12%) children and t(9;22) in 18 (7.4%). Four (1.3%) children died in induction, 6 (2%) died in first remission and 27 (9%) relapsed. After a median follow‐up of 34.5 months (range 0.32–84.5), the estimated 5‐year event free survival and overall survival were 80% and 89%, respectively.
Conclusion
Treatment protocols developed by major cooperative groups and institutions to treat childhood ALL was successfully adapted and suggest that such an approach may be useful in other low‐ and middle‐income countries. Pediatr Blood Cancer 2011; 57: 385–391. © 2011 Wiley‐Liss, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>ISSN: 1545-5017</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.23065</identifier><identifier>PMID: 21360658</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Acute lymphatic leukemia ; Adolescent ; Age ; Blood ; Cancer ; Central nervous system ; Central Nervous System Neoplasms ; Child ; Child, Preschool ; Children ; Data processing ; Female ; Hospitals ; Humans ; Infant ; Jordan ; leukemia ; Lymphocytes B ; Lymphocytes T ; Male ; medical records ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Remission ; Retrospective Studies ; Risk Assessment ; Risk groups ; Survival ; Treatment Outcome</subject><ispartof>Pediatric blood & cancer, 2011-09, Vol.57 (3), p.385-391</ispartof><rights>Copyright © 2011 Wiley‐Liss, Inc.</rights><rights>Copyright © 2011 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4615-4f205afa077f8d1c683eeb44950dd6595d811de098235ad4c73462077ea1924b3</citedby><cites>FETCH-LOGICAL-c4615-4f205afa077f8d1c683eeb44950dd6595d811de098235ad4c73462077ea1924b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.23065$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.23065$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21360658$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halalsheh, Hadeel</creatorcontrib><creatorcontrib>Abuirmeileh, Najyah</creatorcontrib><creatorcontrib>Rihani, Rawad</creatorcontrib><creatorcontrib>Bazzeh, Faiha</creatorcontrib><creatorcontrib>Zaru, Luna</creatorcontrib><creatorcontrib>Madanat, Faris</creatorcontrib><title>Outcome of childhood acute lymphoblastic leukemia in Jordan</title><title>Pediatric blood & cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>Background
Accurate data about childhood acute lymphoblastic leukemia (ALL) in low‐ and middle‐income countries are lacking. Our study is designed to assess survival of childhood ALL at King Hussein Cancer Center (KHCC) using modified St. Jude Children's Research Hospital protocols.
Patients and methods
We reviewed the medical records of children 1–18 years of age who were diagnosed with ALL and treated at KHCC from January 2003 through December 2009. Disease characteristics and outcome were analyzed.
Results
Over a 7‐year period, 300 children with ALL were treated. One hundred and seventy‐three (57.7%) were males and 127 (42.3%) were females. The median age at diagnosis was 5 years. One hundred and fifty‐seven (52.3%) children were classified as low‐risk, 118 (39.3%) were standard‐risk and 25 (8.3%) were high‐risk. Two hundred and sixty‐two (88.5%) children had pre‐B cell phenotype and 34 (11.5%) had T‐cell phenotype. Two hundred and seventy‐three (91.3%) children were classified as having CNS I disease, 24 (8%) had CNS II, and 2 (0.67%) had CNS III. Cytogenetic abnormalities included: t(12;21) in 30 (12%) children and t(9;22) in 18 (7.4%). Four (1.3%) children died in induction, 6 (2%) died in first remission and 27 (9%) relapsed. After a median follow‐up of 34.5 months (range 0.32–84.5), the estimated 5‐year event free survival and overall survival were 80% and 89%, respectively.
Conclusion
Treatment protocols developed by major cooperative groups and institutions to treat childhood ALL was successfully adapted and suggest that such an approach may be useful in other low‐ and middle‐income countries. Pediatr Blood Cancer 2011; 57: 385–391. © 2011 Wiley‐Liss, Inc.</description><subject>Acute lymphatic leukemia</subject><subject>Adolescent</subject><subject>Age</subject><subject>Blood</subject><subject>Cancer</subject><subject>Central nervous system</subject><subject>Central Nervous System Neoplasms</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Data processing</subject><subject>Female</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infant</subject><subject>Jordan</subject><subject>leukemia</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>medical records</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Remission</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk groups</subject><subject>Survival</subject><subject>Treatment Outcome</subject><issn>1545-5009</issn><issn>1545-5017</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90DtPwzAUBWALgSivgT-AsgFDit92xEQrnqooiCIkFsuxHTWQ1CVOBP33GArdYLp3-M4ZDgD7CPYRhPhknps-JpCzNbCFGGUpg0isr36Y9cB2CC-RcsjkJuhhRHjkcgucjrvW-NolvkjMtKzs1HubaNO1LqkW9Xzq80qHtjRJ5bpXV5c6KWfJjW-snu2CjUJXwe393B3weHE-GV6lo_Hl9fBslBrKEUtpgSHThYZCFNIiwyVxLqc0Y9BazjJmJULWwUxiwrSlRhDKcdROowzTnOyAw2XvvPFvnQutqstgXFXpmfNdUFLwL0hwlEf_SgQxlBQLJCI9XlLT-BAaV6h5U9a6WUSkvlZVcVX1vWq0Bz-1XV47u5K_M0ZwsgTvZeUWfzepu8HwtzJdJsrQuo9VQjevigsimHq6vVToQU4m9_fPakA-AdHejhg</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Halalsheh, Hadeel</creator><creator>Abuirmeileh, Najyah</creator><creator>Rihani, Rawad</creator><creator>Bazzeh, Faiha</creator><creator>Zaru, Luna</creator><creator>Madanat, Faris</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201109</creationdate><title>Outcome of childhood acute lymphoblastic leukemia in Jordan</title><author>Halalsheh, Hadeel ; Abuirmeileh, Najyah ; Rihani, Rawad ; Bazzeh, Faiha ; Zaru, Luna ; Madanat, Faris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4615-4f205afa077f8d1c683eeb44950dd6595d811de098235ad4c73462077ea1924b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute lymphatic leukemia</topic><topic>Adolescent</topic><topic>Age</topic><topic>Blood</topic><topic>Cancer</topic><topic>Central nervous system</topic><topic>Central Nervous System Neoplasms</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Data processing</topic><topic>Female</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infant</topic><topic>Jordan</topic><topic>leukemia</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>medical records</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Remission</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk groups</topic><topic>Survival</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halalsheh, Hadeel</creatorcontrib><creatorcontrib>Abuirmeileh, Najyah</creatorcontrib><creatorcontrib>Rihani, Rawad</creatorcontrib><creatorcontrib>Bazzeh, Faiha</creatorcontrib><creatorcontrib>Zaru, Luna</creatorcontrib><creatorcontrib>Madanat, Faris</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halalsheh, Hadeel</au><au>Abuirmeileh, Najyah</au><au>Rihani, Rawad</au><au>Bazzeh, Faiha</au><au>Zaru, Luna</au><au>Madanat, Faris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of childhood acute lymphoblastic leukemia in Jordan</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2011-09</date><risdate>2011</risdate><volume>57</volume><issue>3</issue><spage>385</spage><epage>391</epage><pages>385-391</pages><issn>1545-5009</issn><issn>1545-5017</issn><eissn>1545-5017</eissn><abstract>Background
Accurate data about childhood acute lymphoblastic leukemia (ALL) in low‐ and middle‐income countries are lacking. Our study is designed to assess survival of childhood ALL at King Hussein Cancer Center (KHCC) using modified St. Jude Children's Research Hospital protocols.
Patients and methods
We reviewed the medical records of children 1–18 years of age who were diagnosed with ALL and treated at KHCC from January 2003 through December 2009. Disease characteristics and outcome were analyzed.
Results
Over a 7‐year period, 300 children with ALL were treated. One hundred and seventy‐three (57.7%) were males and 127 (42.3%) were females. The median age at diagnosis was 5 years. One hundred and fifty‐seven (52.3%) children were classified as low‐risk, 118 (39.3%) were standard‐risk and 25 (8.3%) were high‐risk. Two hundred and sixty‐two (88.5%) children had pre‐B cell phenotype and 34 (11.5%) had T‐cell phenotype. Two hundred and seventy‐three (91.3%) children were classified as having CNS I disease, 24 (8%) had CNS II, and 2 (0.67%) had CNS III. Cytogenetic abnormalities included: t(12;21) in 30 (12%) children and t(9;22) in 18 (7.4%). Four (1.3%) children died in induction, 6 (2%) died in first remission and 27 (9%) relapsed. After a median follow‐up of 34.5 months (range 0.32–84.5), the estimated 5‐year event free survival and overall survival were 80% and 89%, respectively.
Conclusion
Treatment protocols developed by major cooperative groups and institutions to treat childhood ALL was successfully adapted and suggest that such an approach may be useful in other low‐ and middle‐income countries. Pediatr Blood Cancer 2011; 57: 385–391. © 2011 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21360658</pmid><doi>10.1002/pbc.23065</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2011-09, Vol.57 (3), p.385-391 |
| issn | 1545-5009 1545-5017 1545-5017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_876192432 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acute lymphatic leukemia Adolescent Age Blood Cancer Central nervous system Central Nervous System Neoplasms Child Child, Preschool Children Data processing Female Hospitals Humans Infant Jordan leukemia Lymphocytes B Lymphocytes T Male medical records Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Remission Retrospective Studies Risk Assessment Risk groups Survival Treatment Outcome |
| title | Outcome of childhood acute lymphoblastic leukemia in Jordan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T16%3A28%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20childhood%20acute%20lymphoblastic%20leukemia%20in%20Jordan&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Halalsheh,%20Hadeel&rft.date=2011-09&rft.volume=57&rft.issue=3&rft.spage=385&rft.epage=391&rft.pages=385-391&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.23065&rft_dat=%3Cproquest_cross%3E876192432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1020842717&rft_id=info:pmid/21360658&rfr_iscdi=true |